{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:09:43Z","timestamp":1770250183977,"version":"3.49.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Medical and Health Technological Project of Shandong Province","award":["No. 202408020154"],"award-info":[{"award-number":["No. 202408020154"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metab"],"DOI":"10.1186\/s40170-025-00418-x","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T14:24:51Z","timestamp":1767795891000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The FGL1-LAG-3 axis attenuates melanoma-induced cachexia in mice"],"prefix":"10.1186","volume":"14","author":[{"given":"Weitao","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lining","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shumei","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tongbin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingchen","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"418_CR1","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489\u201395.","journal-title":"Lancet Oncol"},{"key":"418_CR2","doi-asserted-by":"publisher","first-page":"17105","DOI":"10.1038\/nrdp.2017.105","volume":"4","author":"VE Baracos","year":"2018","unstructured":"Baracos VE, Martin L, Korc M, Guttridge DC, Fearon KCH. Cancer-associated cachexia. Nat Rev Dis Primers. 2018;4:17105.","journal-title":"Nat Rev Dis Primers"},{"key":"418_CR3","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1016\/j.cell.2023.03.028","volume":"186","author":"M Ferrer","year":"2023","unstructured":"Ferrer M, Anthony TG, Ayres JS, Biffi G, Brown JC, Caan BJ, et al. Cachexia: A systemic consequence of progressive, unresolved disease. Cell. 2023;186:1824\u201345.","journal-title":"Cell"},{"key":"418_CR4","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1038\/s42255-024-01167-9","volume":"6","author":"M Berriel Diaz","year":"2024","unstructured":"Berriel Diaz M, Rohm M, Herzig S. Cancer cachexia: multilevel metabolic dysfunction. Nat Metab. 2024;6:2222\u201345.","journal-title":"Nat Metab"},{"key":"418_CR5","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1200\/JCO.20.00611","volume":"38","author":"EJ Roeland","year":"2020","unstructured":"Roeland EJ, Bohlke K, Baracos VE, Bruera E, Del Fabbro E, Dixon S, et al. Management of cancer cachexia: ASCO guideline. J Clin Oncol. 2020;38:2438\u201353.","journal-title":"J Clin Oncol"},{"key":"418_CR6","doi-asserted-by":"publisher","first-page":"e70000","DOI":"10.1002\/jcsm.70000","volume":"16","author":"SY Jang","year":"2025","unstructured":"Jang SY, Choi KM. Impact of adipose tissue and lipids on skeletal muscle in sarcopenia. J Cachexia Sarcopenia Muscle. 2025;16:e70000.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"418_CR7","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.trecan.2018.10.001","volume":"4","author":"SF Schmidt","year":"2018","unstructured":"Schmidt SF, Rohm M, Herzig S, Berriel Diaz M. Cancer cachexia: more than skeletal muscle wasting. Trends Cancer. 2018;4:849\u201360.","journal-title":"Trends Cancer"},{"key":"418_CR8","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1038\/s43018-023-00622-y","volume":"4","author":"J Taylor","year":"2023","unstructured":"Taylor J, Uhl L, Moll I, Hasan SS, Wiedmann L, Morgenstern J, et al. Endothelial Notch1 signaling in white adipose tissue promotes cancer cachexia. Nat Cancer. 2023;4:1544\u201360.","journal-title":"Nat Cancer"},{"key":"418_CR9","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nature13528","volume":"513","author":"S Kir","year":"2014","unstructured":"Kir S, White JP, Kleiner S, Kazak L, Cohen P, Baracos VE, et al. Tumour-derived PTH-related protein triggers adipose tissue Browning and cancer cachexia. Nature. 2014;513:100\u20134.","journal-title":"Nature"},{"key":"418_CR10","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1002\/jcsm.13454","volume":"15","author":"IS Massart","year":"2024","unstructured":"Massart IS, Kouakou AN, Pelet N, Lause P, Schakman O, Loumaye A, et al. Administration of adiponectin receptor agonist adiporon relieves cancer cachexia by mitigating inflammation in tumour-bearing mice. J Cachexia Sarcopenia Muscle. 2024;15:919\u201333.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"418_CR11","doi-asserted-by":"crossref","unstructured":"Wang J, Sanmamed MF, Datar I, Su TT, Ji L, Sun J, et al. Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3. Cell. 2019;176:334\u201347. e12.","DOI":"10.1016\/j.cell.2018.11.010"},{"key":"418_CR12","doi-asserted-by":"crossref","unstructured":"Xi F, Sun H, Peng H, Lian Z, Wei H, Tian Z, et al. Hepatocyte-derived FGL1 accelerates liver metastasis and tumor growth by inhibiting CD8\u2009+\u2009T and NK cells. JCI Insight. 2024;9.","DOI":"10.1172\/jci.insight.173215"},{"key":"418_CR13","doi-asserted-by":"crossref","unstructured":"Hullwegen M, Kleinert M, von Haehling S, Fischer A. GDF15: from biomarker to target in cancer cachexia. Trends Cancer. 2025.","DOI":"10.1016\/j.trecan.2025.06.007"},{"key":"418_CR14","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nrm.2017.76","volume":"18","author":"R Zechner","year":"2017","unstructured":"Zechner R, Madeo F, Kratky D. Cytosolic lipolysis and lipophagy: two sides of the same coin. Nat Rev Mol Cell Biol. 2017;18:671\u201384.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"418_CR15","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/978-981-13-1286-1_11","volume":"1090","author":"X Li","year":"2018","unstructured":"Li X, Sun K. Regulation of lipolysis in adipose tissue and clinical significance. Adv Exp Med Biol. 2018;1090:199\u2013210.","journal-title":"Adv Exp Med Biol"},{"key":"418_CR16","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/s41586-023-06047-y","volume":"617","author":"SN Bilgic","year":"2023","unstructured":"Bilgic SN, Domaniku A, Toledo B, Agca S, Weber BZC, Arabaci DH, et al. EDA2R-NIK signalling promotes muscle atrophy linked to cancer cachexia. Nature. 2023;617:827\u201334.","journal-title":"Nature"},{"key":"418_CR17","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/SPC.0000000000000705","volume":"18","author":"S Agca","year":"2024","unstructured":"Agca S, Kir S. EDA2R-NIK signaling in cancer cachexia. Curr Opin Support Palliat Care. 2024;18:126\u201331.","journal-title":"Curr Opin Support Palliat Care"},{"key":"418_CR18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40364-024-00601-0","volume":"12","author":"J Chen","year":"2024","unstructured":"Chen J, Wu L, Li Y. FGL1 and FGL2: emerging regulators of liver health and disease. Biomark Res. 2024;12:53.","journal-title":"Biomark Res"},{"key":"418_CR19","doi-asserted-by":"publisher","first-page":"344","DOI":"10.4103\/jcrt.jcrt_2674_23","volume":"21","author":"K Hu","year":"2025","unstructured":"Hu K, Zhang G, Niu H, Sun L. Research advances in FGL1\/LAG3 for cancer diagnosis and treatment: from basics to clinical practice. J Cancer Res Ther. 2025;21:344\u201353.","journal-title":"J Cancer Res Ther"},{"key":"418_CR20","doi-asserted-by":"publisher","first-page":"597675","DOI":"10.3389\/fphys.2020.597675","volume":"11","author":"JM Webster","year":"2020","unstructured":"Webster JM, Kempen L, Hardy RS, Langen RCJ. Inflammation and skeletal muscle wasting during cachexia. Front Physiol. 2020;11:597675.","journal-title":"Front Physiol"},{"key":"418_CR21","doi-asserted-by":"publisher","first-page":"185","DOI":"10.2174\/1871530318666180716100543","volume":"19","author":"G Abdelmoemen","year":"2019","unstructured":"Abdelmoemen G, Khodeir SA, Zaki AN, Kassab M, Abou-Saif S, Abd-Elsalam S. Overexpression of Hepassocin in diabetic patients with nonalcoholic fatty liver disease May facilitate increased hepatic lipid accumulation. Endocr Metab Immune Disord Drug Targets. 2019;19:185\u20138.","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"418_CR22","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/lipd.12099","volume":"53","author":"KP Cheng","year":"2018","unstructured":"Cheng KP, Ou HY, Hung HC, Li CH, Fan KC, Wu JS, et al. Unsaturated fatty acids increase the expression of Hepassocin through a signal transducer and activator of transcription 3-Dependent pathway in HepG2 cells. Lipids. 2018;53:863\u20139.","journal-title":"Lipids"},{"key":"418_CR23","doi-asserted-by":"publisher","first-page":"292","DOI":"10.7150\/ijbs.66834","volume":"18","author":"XH Liu","year":"2022","unstructured":"Liu XH, Qi LW, Alolga RN, Liu Q. Implication of the hepatokine, fibrinogen-like protein 1 in liver diseases, metabolic disorders and cancer: the need to Harness its full potential. Int J Biol Sci. 2022;18:292\u2013300.","journal-title":"Int J Biol Sci"},{"key":"418_CR24","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.jhep.2013.06.004","volume":"59","author":"HT Wu","year":"2013","unstructured":"Wu HT, Lu FH, Ou HY, Su YC, Hung HC, Wu JS, et al. The role of Hepassocin in the development of non-alcoholic fatty liver disease. J Hepatol. 2013;59:1065\u201372.","journal-title":"J Hepatol"},{"key":"418_CR25","doi-asserted-by":"publisher","first-page":"106666","DOI":"10.1016\/j.isci.2023.106666","volume":"26","author":"RJ Beck","year":"2023","unstructured":"Beck RJ, Sloot S, Matsushita H, Kakimi K, Beltman JB. Mathematical modeling identifies LAG3 and HAVCR2 as biomarkers of T cell exhaustion in melanoma. iScience. 2023;26:106666.","journal-title":"iScience"},{"key":"418_CR26","doi-asserted-by":"crossref","unstructured":"Davar D, Anderson AC, Diaz-Padilla I. Therapeutic potential of targeting LAG-3 in cancer. J Immunother Cancer. 2025;13.","DOI":"10.1136\/jitc-2025-011652"},{"key":"418_CR27","doi-asserted-by":"crossref","unstructured":"Du J, Chen H, You J, Hu W, Liu J, Lu Q, et al. Proximity between LAG-3 and the T cell receptor guides suppression of T cell activation and autoimmunity. Cell. 2025.","DOI":"10.1016\/j.cell.2025.06.004"},{"key":"418_CR28","doi-asserted-by":"crossref","unstructured":"Yang X, Jeong D, Madeo G, Kumbhar R, Wang N, Niu L, et al. Neuronal LAG3 facilitates pathogenic alpha-synuclein neuron-to-neuron propagation. bioRxiv. 2025.","DOI":"10.1101\/2025.01.03.631221"},{"key":"418_CR29","first-page":"62","volume":"4","author":"P Gulhati","year":"2023","unstructured":"Gulhati P, Schalck A, Jiang S, Shang X, Wu CJ, Hou P, et al. Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1\/CXCR2 results in antitumor immunity and durable response in pancreatic cancer. Nat Cancer. 2023;4:62\u201380.","journal-title":"Nat Cancer"}],"container-title":["Cancer &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40170-025-00418-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40170-025-00418-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40170-025-00418-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T11:05:31Z","timestamp":1770203131000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40170-025-00418-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["418"],"URL":"https:\/\/doi.org\/10.1186\/s40170-025-00418-x","relation":{},"ISSN":["2049-3002"],"issn-type":[{"value":"2049-3002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"1 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the IACUCU of GenePharma Corporation(Suzhou,China)(Approved No.S010020250201115 ).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}